New hope for Hard-to-Treat tumors: targeted drug HRS-6719 enters human trials

NCT ID NCT06922357

Recruiting now Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called HRS-6719 in people with advanced solid tumors that lack a gene called MTAP. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 120 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-6719
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have a specific genetic marker (MTAP deficiency).
What could go wrong: This is an early-phase trial with only 120 participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC SOLID TUMORS

Contacts and locations

Locations

Barbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150081, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.